These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 35101243)

  • 1. COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh.
    Mahmud-Al-Rafat A; Hewins B; Mannan A; Kelvin DJ; Billah MM
    Lancet Infect Dis; 2022 Mar; 22(3):310-312. PubMed ID: 35101243
    [No Abstract]   [Full Text] [Related]  

  • 2. Global South cannot just live with COVID-19.
    Sow SO
    Nat Hum Behav; 2022 Feb; 6(2):170. PubMed ID: 35102354
    [No Abstract]   [Full Text] [Related]  

  • 3. Urgent needs of low-income and middle-income countries for COVID-19 vaccines and therapeutics.
    Lancet Commission on COVID-19 Vaccines and Therapeutics Task Force Members
    Lancet; 2021 Feb; 397(10274):562-564. PubMed ID: 33516284
    [No Abstract]   [Full Text] [Related]  

  • 4. Causes and costs of global COVID-19 vaccine inequity.
    Ferranna M
    Semin Immunopathol; 2024 Jan; 45(4-6):469-480. PubMed ID: 37870569
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVAX can still end COVID-19 vaccine apartheid.
    Gupta A
    Nat Hum Behav; 2022 Feb; 6(2):175. PubMed ID: 35102357
    [No Abstract]   [Full Text] [Related]  

  • 6. COVID-19 vaccines and treatments nationalism: Challenges for low-income countries and the attainment of the SDGs.
    Nhamo G; Chikodzi D; Kunene HP; Mashula N
    Glob Public Health; 2021 Mar; 16(3):319-339. PubMed ID: 33317389
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccine equity and booster doses.
    The Lancet Infectious Diseases
    Lancet Infect Dis; 2021 Sep; 21(9):1193. PubMed ID: 34391506
    [No Abstract]   [Full Text] [Related]  

  • 8. A matter of priority: equitable access to COVID-19 vaccines.
    Holzer F; Luna F; Manriquez T; Biller-Andorno N
    Swiss Med Wkly; 2021 Mar; 151():w20488. PubMed ID: 33715145
    [No Abstract]   [Full Text] [Related]  

  • 9. COVAX no fault compensation program for COVID-19 vaccine injuries in 92 low and middle income countries.
    Mazur A; Benitez S; Chuffart-Finsterwald S; La Rotta R; Hampton LM
    Vaccine; 2021 Dec; 39(49):7128-7130. PubMed ID: 34732277
    [No Abstract]   [Full Text] [Related]  

  • 10. COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience.
    Al-Shaikh A; Muthu N; Aidyralieva C; Profili MC; Bellizzi S
    Vaccine; 2021 Aug; 39(34):4769-4771. PubMed ID: 34281741
    [No Abstract]   [Full Text] [Related]  

  • 11. Preventing pandemics in the world's most vulnerable settings.
    Yamey G; McDade KK; Brennan RJ; Abubakar A; Khan W
    BMJ; 2021 Nov; 375():n2897. PubMed ID: 34824126
    [No Abstract]   [Full Text] [Related]  

  • 12. Novavax's fridge-friendly vaccine impresses.
    Nat Biotechnol; 2021 Jul; 39(7):784. PubMed ID: 34257459
    [No Abstract]   [Full Text] [Related]  

  • 13. Vaccine inequality may undermine the booster programme.
    Haque Z
    BMJ; 2021 Dec; 375():n3118. PubMed ID: 34921004
    [No Abstract]   [Full Text] [Related]  

  • 14. Rationale to continue approving placebo-controlled COVID-19 vaccine trials in LMICs.
    Sisa I; Noblecilla E; Orozco F
    Lancet; 2021 Mar; 397(10277):878. PubMed ID: 33617776
    [No Abstract]   [Full Text] [Related]  

  • 15. Post COVID Antimicrobial Resistance Threat in Lower- and Middle-Income Countries: Bangladesh.
    Mahadi AR
    Front Public Health; 2021; 9():770593. PubMed ID: 34976929
    [No Abstract]   [Full Text] [Related]  

  • 16. The Need for a Practical Approach to Evaluate the Effectiveness of COVID-19 Vaccines for Low- and Middle-Income Countries.
    Nsanzimana S; Gupta A; Uwizihiwe JP; Haggstrom J; Dron L; Arora P; Park JJH
    Am J Trop Med Hyg; 2021 Jul; 105(3):561-563. PubMed ID: 34270458
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sharing Technology and Vaccine Doses to Address Global Vaccine Inequity and End the COVID-19 Pandemic.
    Kavanagh MM; Gostin LO; Sunder M
    JAMA; 2021 Jul; 326(3):219-220. PubMed ID: 34196659
    [No Abstract]   [Full Text] [Related]  

  • 18. Global North and South must work hand in glove to stop COVID-19.
    Alakija A
    Nat Hum Behav; 2022 Feb; 6(2):171. PubMed ID: 35102356
    [No Abstract]   [Full Text] [Related]  

  • 19. Access to COVID-19 Vaccines in High-, Middle-, and Low-Income Countries Hosting Clinical Trials.
    Ramachandran R; Ross JS; Miller JE
    JAMA Netw Open; 2021 Nov; 4(11):e2134233. PubMed ID: 34792596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profiteering from vaccine inequity: a crime against humanity?
    Hassan F; Yamey G; Abbasi K
    BMJ; 2021 Aug; 374():n2027. PubMed ID: 34400410
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.